test

Developmental Therapeutics

Hari Anant Deshpande MD

Assistant Professor of Medicine (Medical Oncology) and of Surgery (Otolaryngology) and Assistant Clinical Professor of Nursing

Clinical Interests

Head and neck cancer; Genitourinary (GU) cancers; sarcomas; thyroid cancer.


Board Certifications

1998
Hematology, Internal Medicine, Board Certified
1999
Medical Oncology, Board Certified
1995
Internal Medicine, Board Certified

Patient Care Locations

hari_deshpandefaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Head and Neck Cancer, Larynx, and Lip, Oral Cavity and PharynxA Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer (ECOG E1305)
Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Prostate Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage IV Bladder Cancer, Stage IV Prostate Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer, and BladderA Randomized Phase III Study of Gemcitabine, Cisplatin, Bevacizumab or Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma (CALGB 90601)
Head and Neck Cancer, Larynx, and Lip, Oral Cavity and PharynxA Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer (RTOG 0920) (CIRB)
Non Small Cell Lung Cancer, Lung Cancer, and LungA Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (CIRB) (SWOG S0819)
Lung Cancer, Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Ill-Defined Sites, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, and ThyroidA Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113

More Clinical Trials...

Edit Profile